Global Urinalysis Market Size (2024 - 2029)

The urinalysis market is anticipated to experience growth over the forecast period, driven by an increasing prevalence of chronic diseases such as diabetes and chronic kidney diseases, alongside a rising adoption of point-of-care testing. The market's expansion was initially hindered by the COVID-19 pandemic, which restricted healthcare services and led to a decline in non-COVID-19-related diagnoses. However, as restrictions eased and healthcare access improved, the market began to recover. Despite these positive trends, the market's growth may be challenged by stringent regulatory frameworks related to urinalysis.

Market Size of Global Urinalysis Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Urinalysis Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
CAGR 7.50 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Urinalysis Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Urinalysis Market Analysis

The urinalysis market is expected to register a CAGR of 7.5% over the forecast period.

The outbreak of COVID-19 impacted the urinalysis market, as hospitals and healthcare services restricted services due to social distancing measures. The unprecedented increase in coronavirus-infected patients reduced access to other primary care services and resulted in a significant drop in non-COVID-19-related diagnoses, such as urinary tract infections or kidney diseases. For instance, according to a research article published in the International Journal of Surgery in July 2021, during the COVID-19 pandemic, urological procedures delayed or postponed included urinary tract infections, stress incontinence, overactive bladder (OAB), and neurogenic bladder. Similarly, according to a December 2021 study published in the ADIAN Journal, fewer patients adopted primary care services, and fewer diagnoses were done, including UTIs. The source also reports that between March 30 and April 24, 2020, the weekly rate of UTI diagnosis per 100,000 population fell from an average of 30-35 to less than 10 in England. Since April, the rate has risen by 50% of the usual rate. Thus, the market witnessed an adverse impact during the pandemic. However, with the ease of restrictions and declining cases of COVID-19, the market started to gain momentum and is expected to continue the upward trend over the forecast period.

The higher burden of chronic diseases such as diabetes and chronic kidney diseases and the rising adaptation of point-of-care testing is expected to be the major contributing factors to the market growth. Urinary tract infection refers to an infection in any part of the urinary system. For instance, as per a December 2021 update by the International Diabetes Federation (IDF), in 2021, approximately 537.0 million adults (20-79 years) had diabetes, which is projected to rise to 643.0 million by 2030 and 783.0 million by 2045. As per the same source, 3 in 4 adults with diabetes live in low- and middle-income countries and almost 1 in 2 (240 million) of them are undiagnosed. The source also reports that diabetes caused 6.7 million deaths in 2021. To identify the glucose level in diabetic people, urine analysis has proven to be an important test. 

Furthermore, increasing cases of chronic kidney diseases across the globe are also expected to propel market growth over the forecast period. For instance, chronic kidney disease (CKD) is a condition that causes reduced kidney function over some time. It may develop over many years and lead to end-stage kidney (or renal) disease (ESRD). It has become an enormous public health issue. For instance, as per the 2021 report by the CDC, more than 15.0% of adults in the United States, amounting to approximately 37.0 million people, were estimated to have CKD. Similarly, in 2021, as per data released on World Kidney Day, a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF), kidney disease affected around 850.0 million people globally. The same source also reported that one in ten adults has chronic kidney disease (CKD). The global burden of CKD is continuously increasing and is projected to become the 5th most common cause of years of life lost globally by 2040. 

While the market is poised for growth, stringent regulatory frameworks related to urinalysis may hinder market growth over the forecast period.

Urinalysis Industry Segmentation

Urinalysis is a test performed for detecting disorders related to the kidney, urinary tract infection, or diabetes. The urinalysis market is segmented by Product Type (Instruments and Consumables), Test Type (Biochemical, Pregnancy & Fertility, and Sediment), Application (Disease Screening and Pregnancy & Fertility), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

By Product Type
Instruments
Automated Analyser
Semi-automated Analyzer
Point of Care Analyzer
Consumables
Reagents & Kits
Dipsticks
Disposables
By Test Type
Biochemical
Pregnancy & Fertility
Sediment
By Application
Disease Screening
Pregnancy & Fertility
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Urinalysis Market Size Summary

The urinalysis market is poised for significant growth, driven by the increasing prevalence of chronic diseases such as diabetes and chronic kidney conditions, alongside the rising adoption of point-of-care testing. The market experienced a temporary setback during the COVID-19 pandemic due to restricted healthcare services and a decline in non-COVID-19-related diagnoses. However, as restrictions eased and COVID-19 cases declined, the market began to recover and is expected to continue its upward trajectory. The demand for urinalysis is further bolstered by its critical role in diagnosing conditions like urinary tract infections and its expanding application in pregnancy and fertility testing. Despite the promising growth prospects, the market faces challenges from stringent regulatory frameworks that could impede its expansion.

North America is anticipated to hold a significant share of the global urinalysis market, attributed to the aging population and the high prevalence of chronic kidney diseases in the region. The need for effective diagnosis and management of these conditions is expected to drive market demand. Key factors contributing to market growth in the United States include the high incidence of urinary tract infections, a growing geriatric population, and strategic initiatives by major players such as product launches and partnerships. The market is moderately competitive, with several global and regional players like Cardinal Health Inc., Roche Diagnostics, and Sysmex Corporation actively enhancing their market presence. These companies are introducing innovative products, such as automated urine particle analyzers and at-home pregnancy test kits, to cater to the evolving needs of the healthcare sector.

Explore More

Global Urinalysis Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Burden of Chronic Kidney Disease

      2. 1.2.2 Rising Preference for Point of Care Testing

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulatory framework

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size - Value in USD Million)

    1. 2.1 By Product Type

      1. 2.1.1 Instruments

        1. 2.1.1.1 Automated Analyser

        2. 2.1.1.2 Semi-automated Analyzer

        3. 2.1.1.3 Point of Care Analyzer

      2. 2.1.2 Consumables

        1. 2.1.2.1 Reagents & Kits

        2. 2.1.2.2 Dipsticks

        3. 2.1.2.3 Disposables

    2. 2.2 By Test Type

      1. 2.2.1 Biochemical

      2. 2.2.2 Pregnancy & Fertility

      3. 2.2.3 Sediment

    3. 2.3 By Application

      1. 2.3.1 Disease Screening

      2. 2.3.2 Pregnancy & Fertility

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle-East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle-East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Urinalysis Market Size FAQs

The Global Urinalysis Market is projected to register a CAGR of 7.5% during the forecast period (2024-2029)

Cardinal Health Inc., Roche Diagnostics , Sysmex Corporation, Beckman Coulter Inc. and Arkray Inc. are the major companies operating in the Global Urinalysis Market.

Urinalysis Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)